Skip to main content

Xcell Biosciences Closes $12 Million Series A Funding Round

NEW YORK (GenomeWeb) – Xcell Biosciences said today that it has closed a $12 million Series A private equity financing round, led by HBM Genomics.

Along with HBM, the round also included continued participation from all of Xcell's major existing investors, the company said.

Xcell will use the funds to launch its commercial platform worldwide, as well as to expand its US sales force. The company's platform, called the Avatar system, enables propagation and gene editing in hard to transfect cell types, and is currently used for translational research, clinical diagnostics development, and cell therapy applications, the firm said.

"These new funds will enable us to expand our reach with clinical research customers in oncology, stem cell biology, and immunology, as well as customers engaged in cell therapy development and regenerative medicine," Xcell CEO Brian Feth said in a statement.

With the closing of the funding round, Xcell also said that Saeid Akhtari, managing director of HBM Genomics, will join its board of directors.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.